Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-06-2014 | Head and Neck

Prognostic value of preoperative ¹⁸F-FDG PET/CT for primary head and neck squamous cell carcinoma

Authors: Young-Hoon Joo, Ie-Ryung Yoo, Kwang-Jae Cho, Jun-Ook Park, In-Chul Nam, Chung-Soo Kim, Min-Sik Kim

Published in: European Archives of Oto-Rhino-Laryngology | Issue 6/2014

Abstract

¹⁸F-FDG PET/CT is clinically useful in the initial staging and follow-up of patients with head and neck squamous cell carcinoma (HNSCC). We studied the potential prognostic significance of preoperative ¹⁸F-FDG PET/CT in HNSCC. The medical records of 294 patients who underwent preoperative ¹⁸F-FDG PET/CT for HNSCC were retrospectively reviewed. The median SUV_max of the primary lesions (SUV_max-p) and cervical lymph nodes (SUV_max-n) was 7.98 ± 5.04 (range 1.2–28.7) and 3.34 ± 3.70 (range 1.0–20.4), respectively. There was a significant difference between with and without recurrence in SUV_max-p (11.14 ± 5.36 vs. 6.78 ± 4.35, p < 0.001) and SUV_max-n (5.60 ± 4.22 vs. 1.75 ± 1.46, p < 0.001). The cut-off values of SUV_max-p and SUV_max-n in the context of recurrence and cancer-related death were 8.5 and 3.5. The 5-year disease-free survival of patients with SUV_max-p < 8.5 and SUV_max-n < 3.5 was 79 and 79 %, respectively, whereas that of patients with SUV_max-p ≥ 8.5 and SUV_max-n ≥ 3.5 was 39 and 30 %, respectively. Multivariate analysis confirmed the significant association between 5-year disease-free survival and SUV_max-p ≥ 8.5 (hazard ratio (HR) 2.68, p < 0.001) and SUV_max-n ≥ 3.5 (HR 2.29, p = 0.007). Furthermore, SUV_max-p ≥ 8.5 (HR 3.20, p = 0.012) and SUV_max-n ≥ 3.5 (HR 2.14, p < 0.001) were associated with 5-year overall survival. ¹⁸F-FDG PET/CT cut-off values of SUV_max-p ≥ 8.5 or SUV_max-n ≥ 3.5 are associated with a recurrence and survival in HNSCC.

Jain S, Khuri FR, Shin DM (2004) Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer 28:265–286PubMedCrossRef

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMedCrossRef

Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31:195–201PubMedCrossRef

Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF et al (2005) 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 46:1136–1143PubMed

Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM et al (2006) Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 24:4371–4376PubMedCrossRef

Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S et al (2003) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015–1024PubMedCrossRef

Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59:1295–1300PubMedCrossRef

Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY et al (2009) Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 73:764–771PubMedCrossRef

Hoshikawa H, Mitani T, Nishiyama Y, Yamamoto Y, Ohkawa M, Mori N (2009) Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 36:192–198PubMedCrossRef

10.

Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911PubMed

11.

Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S et al (2002) Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199–4208PubMedCrossRef

12.

Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, el El-Ghazi A, Lehmann W et al (2002) Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20:1398–1404PubMedCrossRef

13.

Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY et al (2007) Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48:752–757PubMedCrossRef

14.

Zasadny KR, Wahl RL (1993) Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 189:847–850PubMed

15.

Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843–850PubMedCrossRef

16.

Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK et al (1998) Precisely defining high-risk operable head-and-neck tumors based on RTOG#85-03 and RTOG#88-24: targets for postoperative chemoradiotherapy? Head Neck 20:588–594PubMedCrossRef

17.

Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH et al (2001) Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and neck cancer. Int J Radiat Oncol Biol Phys 51:571–578PubMedCrossRef

18.

Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA, Weinstein GS et al (2002) Importance of treatment package time in surgery and postoperative radiation therapy for squamous cell carcinoma of the head and neck. Head Neck 24:115–126PubMedCrossRef

19.

Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P et al (2003) SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 44:1044–1050PubMed

20.

Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34:1–6PubMed

Title: Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma
Authors: Young-Hoon Joo
Ie-Ryung Yoo
Kwang-Jae Cho
Jun-Ook Park
In-Chul Nam
Chung-Soo Kim
Min-Sik Kim
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Oto-Rhino-Laryngology / Issue 6/2014
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-013-2605-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prognostic value of preoperative ¹⁸F-FDG PET/CT for primary head and neck squamous cell carcinoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results

Initial experiences with endoscopic rhino-neurosurgery in Amsterdam

Bronchial asthma control after argon plasma coagulation turbinectomy in patients with chronic rhinitis

Intratympanic gentamicin treatment ‘as needed’ for Meniere’s disease. Long-term analysis using the Kaplan–Meier method

Effectiveness of intratympanic dexamethasone for refractory sudden sensorineural hearing loss

Individualized optimal surgical extent of the lateral neck in papillary thyroid cancer with lateral cervical metastasis